Newsroom & Blog
Visiopharm and Ultivue form co-marketing partnership, raising the bar for immunoprofiling insights
Visiopharm presents innovations for tissue biomarker standardization, and launches early access program at upcoming USCAP 2021 virtual meeting
Visiopharm appoints James Mansfield as senior vice president, research business development
The Region of Southern Denmark turns to Visiopharm to improve cancer-diagnostic turn-around times and precision
Visiopharm’s AI-powered image analysis software selected to analyze the largest collection of human pathology specimens in the world
Visiopharm’s pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.
Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, and the United States.